| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.2 |
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.051 | 0.2 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.051 | 0.2 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.2 |